Abzena announces a research and licence agreement with Tmunity Therapeutics
a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancersRead More
Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena
The manufacture of this product took place at Abzena’s site in San Diego, CA but utilised significant bioanalytics and bioassay expertise from Abzena’s Cambridge, UK site including product characterisation, binding, potency and stability assays.Read More
Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation.Read More
Technologies and Solutions
Abzena provides proprietary technologies and complementary solutions to organisations involved in the development of biopharmaceutical products.
Latest News and Events
Abzena presents its latest research and exhibits at events all over the world.
Find out where we are next and our latest news below.
Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability
Antibody Engineering & Therapeutics
9 December 2018
Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment
13 December 2018
Resources and Downloads
Find our latest videos, brochures and fact sheets in our resources section.
Download our Brochure
Technology & Solutions BrochureDownload File
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs)…Read More
Cell Line Development Lab Tour
Abzena has over 10 years experience in Cell Line Development for customers and has completed…